[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556219":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":39,"responsibleParty":84,"collaborators":86,"id":90,"slug":11,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":11,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High-resolution anoscopy","OTHER",null,[13],"Procedure: High-resolution anoscopy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"PROCEDURE","The study includes 2 visits:\n\n* a medical consultation for inclusion\n* a proctology consultation including the performance of an AHR associated or not with biopsy sampling",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Caroline Lascoux-Combe, Dr","Assistance Publique - Hôpitaux de Paris","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":27},"David Veyer, Pharm D,PhD","Hôpital Européen Georges-Pompidou","STUDY_DIRECTOR",[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Fatoumata Coulibaly","CONTACT","0144236110","+33","fatoumata.coulibay@inserm.fr",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Mathilde Ghislain, MSc","0145595229","mathilde.ghislain@inserm.fr",[40,58,72],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hôpital de la Croix Rousse - SMIT","RECRUITING","Lyon","69004","France",{"type":47,"coordinates":48},"Point",[49,50],4.84789,45.74906,{"lat":50,"lon":49},[53,56],{"name":54,"role":31,"phone":11,"phoneExt":11,"email":55},"Stanislas Ogoudjobi","stanislas.ogoudjobi@chu-lyon.fr",{"name":57,"role":23,"phone":11,"phoneExt":11,"email":11},"Dulce Alfaiate, Dr",{"facility":59,"status":42,"city":60,"state":11,"zip":61,"country":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hôpital Saint-Louis - SMIT","Paris","75010",{"type":47,"coordinates":63},[64,65],2.3488,48.85341,{"lat":65,"lon":64},[68,71],{"name":69,"role":31,"phone":11,"phoneExt":11,"email":70},"Bénédicte Loze","benedicte.loze@aphp.fr",{"name":21,"role":23,"phone":11,"phoneExt":11,"email":11},{"facility":73,"status":42,"city":60,"state":11,"zip":74,"country":45,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Hôpital Tenon - SMIT","75020",{"type":47,"coordinates":76},[64,65],{"lat":65,"lon":64},[79,82],{"name":80,"role":31,"phone":11,"phoneExt":11,"email":81},"Thibaut Pélagie","pelagie.thibaut@aphp.fr",{"name":83,"role":23,"phone":11,"phoneExt":11,"email":11},"Gilles Pialoux, Pr",{"type":85,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[87],{"name":88,"class":89},"INSERM SC10-US19","UNKNOWN","100556219",false,"NCT06522256","Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and\u002For Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial","HPVsign","Inclusion Criteria:\n\n* Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;\n* Informed and written signed consent\n* Participant with regular health insurance\n\nExclusion Criteria:\n\n* Participant under guardianship or curatorship\n* Participant with free State medical assistance\n* Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.",true,"ALL","18 Years",{"count":100,"type":101},100,"ESTIMATED","INTERVENTIONAL",[104],"NA","HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and\u002For anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and\u002For diagnosed since the end of participation in the ANRS IPERGAY trial.",[107,108],"HPV Infection","Anal Cancer",[110],"HSIL","2025-11-27",{"date":113,"type":114},"2025-12-04","ACTUAL",{"date":116,"type":114},"2025-03-20",{"date":118,"type":101},"2027-07-30",{"name":5,"class":6},3]